NZ702127A - Methods and compositions for diagnosis and treatment of cancer - Google Patents

Methods and compositions for diagnosis and treatment of cancer

Info

Publication number
NZ702127A
NZ702127A NZ702127A NZ70212710A NZ702127A NZ 702127 A NZ702127 A NZ 702127A NZ 702127 A NZ702127 A NZ 702127A NZ 70212710 A NZ70212710 A NZ 70212710A NZ 702127 A NZ702127 A NZ 702127A
Authority
NZ
New Zealand
Prior art keywords
acid sequence
peptide
tumour antigen
amino acid
nucleic acid
Prior art date
Application number
NZ702127A
Inventor
Stefan Woll
Michael Koslowski
Ugur Sahin
Korden Walter
Ozlem Tureci
Gerd Helftenbein
Gabriela-Elena Oprea
Original Assignee
Ganymed Pharmaceuticals Ag
Univ Mainz Johannes Gutenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09002452A external-priority patent/EP2221375A1/en
Application filed by Ganymed Pharmaceuticals Ag, Univ Mainz Johannes Gutenberg filed Critical Ganymed Pharmaceuticals Ag
Publication of NZ702127A publication Critical patent/NZ702127A/en

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed is a method for diagnosis, detection or monitoring of a tumour disease comprising the detection of and/or determination of the quantity of one or more parameters selected from the group consisting of: (i) a nucleic acid which codes for a peptide comprising the amino acid sequence of a tumour antigen, (ii) a peptide comprising the amino acid sequence of a tumour antigen, (iii) an antibody which binds to a peptide comprising the amino acid sequence of a tumour antigen, (iv) a T cell that recognizes a peptide comprising the amino acid sequence of a tumour antigen or a functional fragment of said peptide and/or (v) a cell which presents a peptide comprising the amino acid sequence of a tumour antigen or a functional fragment of said peptide, -in a biological sample isolated from a patient, wherein the biological sample is from a tissue or organ and wherein the cells when the tissue or organ is free of tumours do not express said tumour antigen and/or a nucleic acid encoding said tumour antigen, -wherein said tumour antigen comprises an amino acid sequence encoded by a nucleic acid which comprises the nucleic acid sequence according to SEQ ID NO: 1 of the sequence listing or a functional variant of said nucleic acid sequence, and -wherein the detection of the presence of the one or more parameters in the biological sample, and/or the determination of an increased amount of the one or more parameters in the biological sample, is indicative for the presence of the tumour disease.
NZ702127A 2009-02-20 2010-02-19 Methods and compositions for diagnosis and treatment of cancer NZ702127A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15416709P 2009-02-20 2009-02-20
EP09002452A EP2221375A1 (en) 2009-02-20 2009-02-20 Methods and compositions for diagnosis and treatment of cancer
US23184309P 2009-08-06 2009-08-06
EP09010164 2009-08-06
US26013509P 2009-11-11 2009-11-11
EP09014135 2009-11-11
NZ61072010 2010-02-19

Publications (1)

Publication Number Publication Date
NZ702127A true NZ702127A (en) 2016-05-27

Family

ID=56132563

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ702127A NZ702127A (en) 2009-02-20 2010-02-19 Methods and compositions for diagnosis and treatment of cancer

Country Status (1)

Country Link
NZ (1) NZ702127A (en)

Similar Documents

Publication Publication Date Title
MX2009002151A (en) Antagonistic human light-specific human monoclonal antibodies.
MX337991B (en) Cancer detection method.
EA201001874A1 (en) A METHOD FOR DIAGNOSTIC MALIGNANT NUMER FORMATION, EXPRESSING THE HER2 RECEPTOR OR HIS REDUCED OPTIONS
JP2016536330A5 (en)
WO2010023327A4 (en) Method for obtaining oligonucleotide aptamers and uses thereof
HRP20231525T1 (en) Methods and compositions for diagnosis and treatment of cancer
MX2009009379A (en) Methods and compositions for treating tumor diseases.
RU2012132442A (en) ANTIBODY TO CD27
DE502005009602D1 (en) IDENTIFICATION OF SURFACE ASSOCIATED ANTIGENES FOR TUMOR DIAGNOSIS AND THERAPY
MX2012004084A (en) Siglec 15 antibodies in treating bone loss-related disease.
JP2015516813A5 (en)
JP2012115275A5 (en)
MX2012014739A (en) Novel antibody for the diagnosis and/or prognosis of cancer.
CA2793647A1 (en) Prophylaxis of colorectal and gastrointestinal cancer
JP2013507970A5 (en)
DE602006012995D1 (en) BREAST CANCER DIAGNOSTIC PROCEDURE
RU2013113314A (en) METHODS FOR IDENTIFICATION OF ANTIBODIES AGAINST HE4 AND METHODS FOR DIAGNOSTIC AND / OR FORECASTING CONDITIONS ASSOCIATED WITH EXPRESS HE4 CELLS
WO2010135431A3 (en) Compositions, devices, and methods related to prostate-specific membrane antigen
RU2011123655A (en) FULLY HUMANIZED ANTIBODIES AGAINST N-CADHERINE
EP1951891A4 (en) Cancer antigen mage-a9 and uses thereof
RU2013104137A (en) BARD1 ISOFORMS IN LUNG AND COLORECTAL CANCER AND THEIR APPLICATION
RU2010135525A (en) A NEW MOLECULE ASSOCIATED WITH A METASTATIC HUMAN TUMOR, METHODS OF DETECTION AS AN ACTIVATED GENE, SO AND PROTEIN AND HINDER OF EXPRESSION OF GENES
NZ702127A (en) Methods and compositions for diagnosis and treatment of cancer
JP2010514421A5 (en)
JP2007215412A (en) Method for judging malignant metastatic stomach cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 FEB 2017 BY JAMES + WELLS

Effective date: 20161222

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 FEB 2018 BY JAMES + WELLS

Effective date: 20170214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 FEB 2019 BY JAMES + WELLS

Effective date: 20180219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 FEB 2020 BY COMPUTER PACKAGES INC

Effective date: 20190131

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 FEB 2021 BY COMPUTER PACKAGES INC

Effective date: 20200131

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 FEB 2022 BY COMPUTER PACKAGES INC

Effective date: 20210130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 FEB 2023 BY COMPUTER PACKAGES INC

Effective date: 20220130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 FEB 2024 BY COMPUTER PACKAGES INC

Effective date: 20230130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 FEB 2025 BY COMPUTER PACKAGES INC

Effective date: 20240130

ASS Change of ownership

Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERS, DE

Effective date: 20240320

Owner name: ASTELLAS PHARMA INC, JP

Effective date: 20240320